SCHEMBL1786548

SCHEMBL1786548

COC(=O)c1cc(-c2cccc(N(C)C)n2)ccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.53
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
MAPT P10636 4/20 0.46
LMNA P02545 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
KDM4E B2RXH2 2/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
NPC1 O15118 1/20 0.43
NFKB1 P19838 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PFKFB3 Q16875 1/20 0.43
NTRK1 P04629 3/20 0.42
NQO2 P16083 2/20 0.42
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1785417 0.86 CNR1 (0.53) CNR1NTRK1SMO
SCHEMBL17239563 0.81 CNR2 (0.45) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL6717982 0.80 CNR1 (0.55) CNR1NPC1RAB9A
SCHEMBL17239418 0.80 LMNA (0.44) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL17239627 0.78 NTRK1 (0.55) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL17239477 0.77 SMN1; SMN2 (0.41) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL17239604 0.77 NTRK1 (0.54) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL1788339 0.76 P2RX7 (0.58) CNR1MEN1KMT2AMAPTLMNA
SCHEMBL17186883 0.72 SMN1; SMN2 (0.49) CNR1MEN1KMT2AMAPTLMNA
SCHEMBL4436292 0.72 NOTUM (0.57) CNR1MAPTSMN1; SMN2KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2013-08-08 US disclosed
EP-2607357-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS Astrazeneca AB (SE) 2013-06-26 EP disclosed
US-20120115845-A1 THERAPEUTIC AGENTS ALLEN JACK MCQUEEN (GB) 2012-05-10 US disclosed
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2011-05-26 US disclosed
CN-101883762-A Benzothiazoles as modulators of growth hormone releasing hormone receptors ASTRAZENECA AB 2010-11-10 CN disclosed
EP-2205576-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS AstraZeneca AB (SE) 2010-07-14 EP disclosed
US-20090186870-A1 Therapeutic Agents - 802 ASTRAZENECA AB (SE) 2009-07-23 US disclosed
WO-2009047558-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R CNR1 237/4885MEN1 2250/4885KMT2A 1721/4885
US-20120115845-A1 THERAPEUTIC AGENTS GPR119, MC2R, MC4R CNR1 572/4885MEN1 692/4885KMT2A 3139/4885
US-20090186870-A1 Therapeutic Agents - 802 GPR119, SLC5A2, MC2R CNR1 247/4885MEN1 1253/4885KMT2A 2304/4885
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R CNR1 237/4885MEN1 2250/4885KMT2A 1721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.